IRIC - Institute for Research in Immunology and Cancer

Primary navigation

  • About
    • Our Institute
    • Governance
    • News
    • Events
    • Grants
  • Research
    • Importance of research
    • Principal Investigators
    • Research topics
    • Platforms and infrastructures
    • Publications
    • Lectures
  • Training
    • Study at IRIC
    • Our programs
    • Submit your application
  • Valorization
  • Careers
    • Available positions
    • Spontaneous application
  • Support research
    • Make a donation
    • Get involved
    • Other ways to give
    • Donor impact
    • Our donors
  • Directory
  • Tools
  • Press
  • Contact
  • Support research
    • Make a donation
    • Get involved
    • Other ways to give
    • Donor impact
    • Our donors
  • Search
  • FR

Breadcrumb

  • Home
  • Search
  • Home

Search

137 results


Publications — IRIC October 31, 2022

Cancer cells hijack RNA processing to rewrite the message.

Borden K
Biochem Soc Trans 2022-10-31 ;50( 5 ):1447-1456.


Publications — IRIC September 21, 2022

Unorthodox PCNA Binding by Chromatin Assembly Factor 1.

Gopinathan Nair A, Rabas N, Lejon S, Homiski C, Osborne MJ, Cyr N, Sverzhinsky A, Melendy T, Pascal JM, Laue ED, Borden K, Omichinski JG, Verreault A
Int J Mol Sci 2022-09-21 ;23( 19 ):.


Publications — IRIC August 1, 2022

The search for genetic dark matter and lessons learned from the journey.

Borden K
Biochem Cell Biol 2022-08-01 ;100( 4 ):276-281.


Publications — IRIC January 10, 2022

Identification and Characterization of the Interaction Between the Methyl-7-Guanosine Cap Maturation Enzyme RNMT and the Cap-Binding Protein eIF4E.

Osborne MJ, Volpon L, Memarpoor-Yazdi M, Pillay S, Thambipillai A, Czarnota S, Culjkovic-Kraljacic B, Trahan C, Oeffinger M, Cowling VH, Borden K
J Mol Biol 2022-01-10 ;434( 5 ):167451.


Publications — IRIC January 1, 2022

Subcellular Fractionation Suitable for Studies of RNA and Protein Trafficking.

Culjkovic-Kraljacic B, Borden K
Methods Mol Biol 2022-01-01 ;2502:91-104.


Publications — IRIC December 8, 2021

The Cap-Binding Complex CBC and the Eukaryotic Translation Factor eIF4E: Co-Conspirators in Cap-Dependent RNA Maturation and Translation.

Mars JC, Ghram M, Culjkovic-Kraljacic B, Borden K
Cancers (Basel) 2021-12-08 ;13( 24 ):.


Publications — IRIC October 1, 2021

1H, 13C and 15N chemical shift assignments of the C-terminal domain of human UDP-Glucuronosyltransferase 2B7 (UGT2B7-C).

Osborne MJ, Rahardjo AK, Volpon L, Borden K
Biomol NMR Assign 2021-10-01 ;15( 2 ):323-328.


Publications — IRIC December 25, 2020

The Nuclear Pore Complex and mRNA Export in Cancer.

Borden K
Cancers (Basel) 2020-12-25 ;13( 1 ):.


Publications — IRIC October 27, 2020

The eukaryotic translation initiation factor eIF4E elevates steady-state m7G capping of coding and noncoding transcripts.

Culjkovic-Kraljacic B, Skrabanek L, Revuelta MV, Gasiorek J, Cowling VH, Cerchietti L, Borden K
Proc Natl Acad Sci U S A 2020-10-27 ;117( 43 ):26773-26783.


Publications — IRIC June 4, 2020

The diversity, plasticity, and adaptability of cap-dependent translation initiation and the associated machinery.

Borden K, Volpon L
RNA Biol 2020-06-04 ;1-13.


Publications — IRIC December 7, 2019

Structural studies of the eIF4E-VPg complex reveal a direct competition for capped RNA: Implications for translation.

Coutinho de Oliveira L, Volpon L, Rahardjo AK, Osborne MJ, Culjkovic-Kraljacic B, Trahan C, Oeffinger M, Kwok B, Borden K
Proc. Natl. Acad. Sci. U.S.A. 2019-12-07 ;116( 48 ):24056-24065.


Publications — IRIC April 30, 2019

Nuclear eIF4E Stimulates 3’-End Cleavage of Target RNAs.

Davis MR, Delaleau M, Borden K
Cell Rep 2019-04-30 ;27( 5 ):1397-1408.e4.


Publications — IRIC April 1, 2019

Chemical shift assignment of the viral protein genome-linked (VPg) from potato virus Y.

Coutinho de Oliveira L, Volpon L, Osborne MJ, Borden K
Biomol NMR Assign 2019-04-01 ;13( 1 ):9-13.


Publications — IRIC March 15, 2019

GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs.

Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden K
ACS Chem. Biol. 2019-03-15 ;14( 3 ):348-355.


Publications — IRIC March 14, 2019

CDK9 and mTOR: trading places.

Borden K
Blood 2019-03-14 ;133( 11 ):1167-1168.


Publications — IRIC March 1, 2019

Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.

Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden K, Felix CA
Oncogene 2019-03-01 ;38( 13 ):2241-2262.


Publications — IRIC January 18, 2019

Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.

Osborne MJ, Coutinho de Oliveira L, Volpon L, Zahreddine HA, Borden K
J. Mol. Biol. 2019-01-18 ;431( 2 ):258-272.


Publications — IRIC January 1, 2019

Biochemical and Structural Insights into the Eukaryotic Translation Initiation Factor eIF4E.

Volpon L, Osborne MJ, Borden K
Curr. Protein Pept. Sci. 2019-01-01 ;20( 6 ):525-535.


Publications — IRIC November 5, 2018

The Impact of Post-transcriptional Control: Better Living Through RNA Regulons.

Culjkovic-Kraljacic B, Borden K
Front Genet 2018-11-05 ;9:512.


Publications — IRIC October 1, 2018

Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A).

Osborne MJ, Coutinho de Oliveira L, Volpon L, Borden K
Biomol NMR Assign 2018-10-01 ;12( 2 ):315-318.


Publications — IRIC September 11, 2018

BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.

Ngeow KC, Friedrichsen HJ, Li L, Zeng Z, Andrews S, Volpon L, Brunsdon H, Berridge G, Picaud S, Fischer R, Lisle R, Knapp S, Filippakopoulos P, Knowles H, Steingrímsson E, Borden K, Patton EE, Goding CR
Proc. Natl. Acad. Sci. U.S.A. 2018-09-11 ;115( 37 ):E8668-E8677.


Publications — IRIC July 11, 2018

A TFEB nuclear export signal integrates amino acid supply and glucose availability.

Li L, Friedrichsen HJ, Andrews S, Picaud S, Volpon L, Ngeow K, Berridge G, Fischer R, Borden K, Filippakopoulos P, Goding CR
Nat Commun 2018-07-11 ;9( 1 ):2685.


Publications — IRIC November 7, 2017

The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity.

Zahreddine HA, Culjkovic-Kraljacic B, Emond A, Pettersson F, Midura R, Lauer M, Del Rincon S, Cali V, Assouline S, Miller WH, Hascall V, Borden K
Elife 2017-11-07 ;6:.


Publications — IRIC June 1, 2017

A biochemical framework for eIF4E-dependent mRNA export and nuclear recycling of the export machinery.

Volpon L, Culjkovic-Kraljacic B, Sohn HS, Blanchet-Cohen A, Osborne MJ, Borden K
RNA 2017-06-01 ;23( 6 ):927-937.


Publications — IRIC August 10, 2016

The eukaryotic translation initiation factor eIF4E wears a “cap” for many occasions.

Borden K
Translation (Austin) 2016-08-10 ;4( 2 ):e1220899.


Publications — IRIC May 10, 2016

Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E.

Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, Chook YM, Borden K
Proc. Natl. Acad. Sci. U.S.A. 2016-05-10 ;113( 19 ):5263-8.


Publications — IRIC February 18, 2016

Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.

Culjkovic-Kraljacic B, Fernando TM, Marullo R, Calvo-Vidal N, Verma A, Yang S, Tabbò F, Gaudiano M, Zahreddine H, Goldstein RL, Patel J, Taldone T, Chiosis G, Ladetto M, Ghione P, Machiorlatti R, Elemento O, Inghirami G, Melnick A, Borden K, Cerchietti L
Blood 2016-02-18 ;127( 7 ):858-68.


Publications — IRIC August 28, 2015

Multiple Export Mechanisms for mRNAs.

Delaleau M, Borden K
Cells 2015-08-28 ;4( 3 ):452-73.


Publications — IRIC May 15, 2015

Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.

Zahreddine HA, Borden K
Clin. Cancer Res. 2015-05-15 ;21( 10 ):2207-10.


Publications — IRIC February 24, 2015

Sonic Hedgehog factor Gli1: As good as resistant.

Zahreddine HA, Culjkovic-Kraljacic B, Borden K
Mol Cell Oncol 2015-02-24 ;2( 1 ):e961827.


Publications — IRIC January 1, 2015

A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, Lau CJ, Zahreddine HA, Miller WH, Borden K
Haematologica 2015-01-01 ;100( 1 ):e7-9.


Publications — IRIC January 1, 2015

The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.

Osborne MJ, Borden K
Immunol. Rev. 2015-01-01 ;263( 1 ):210-23.


Publications — IRIC December 15, 2014

When Will Resistance Be Futile?

Borden K
Cancer Res. 2014-12-15 ;74( 24 ):7175-7180.


Publications — IRIC November 18, 2014

MNKs act as a regulatory switch for eIF4E1 and eIF4E3 driven mRNA translation in DLBCL.

Landon AL, Muniandy PA, Shetty AC, Lehrmann E, Volpon L, Houng S, Zhang Y, Dai B, Peroutka R, Mazan-Mamczarz K, Steinhardt J, Mahurkar A, Becker KG, Borden K, Gartenhaus RB
Nat Commun 2014-11-18 ;5:5413.


Publications — IRIC August 15, 2014

Inducible drug modification: A new form of resistance.

Culjkovic-Kraljacic B, Zahreddine HA, Borden K
Cell Cycle 2014-08-15 ;13( 16 ):2485-6.


Publications — IRIC July 24, 2014

TIF-90 tips the balance in rRNA synthesis.

Borden K
Blood 2014-07-24 ;124( 4 ):467-8.


Publications — IRIC July 3, 2014

The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.

Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchietti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, Jordan CT, Miller WH, Borden K
Nature 2014-07-03 ;511( 7507 ):90-3.


Publications — IRIC March 1, 2014

LIMD2 Is a Small LIM-Only Protein Overexpressed in Metastatic Lesions That Regulates Cell Motility and Tumor Progression by Directly Binding to and Activating the Integrin-Linked Kinase.

Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, Herlyn M, Caton AJ, Fredericks W, Malkowicz B, Paterno CS, Carolin AS, Speicher DW, Skordalakes E, Huang Q, Dedhar S, Borden K, Rauscher FJ
Cancer Res. 2014-03-01 ;74( 5 ):1390-403.


Publications — IRIC October 1, 2013

The eukaryotic translation initiation factor eIF4E is a direct transcriptional target of NF-κB and is aberrantly regulated in acute myeloid leukemia.

Hariri F, Arguello M, Volpon L, Culjkovic-Kraljacic B, Nielsen TH, Hiscott J, Mann KK, Borden K
Leukemia 2013-10-01 ;27( 10 ):2047-55.


Publications — IRIC September 1, 2013

Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma.

Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, Wyman S, Leser M, Shaknovich R, Chadburn A, Tabbo F, Godley LA, Gascoyne RD, Borden K, Inghirami G, Leonard JP, Melnick A, Cerchietti L
Cancer Discov 2013-09-01 ;3( 9 ):1002-1019.


Publications — IRIC July 1, 2013

Aiding and abetting cancer: mRNA export and the nuclear pore.

Culjkovic-Kraljacic B, Borden K
Trends Cell Biol. 2013-07-01 ;23( 7 ):328-35.


Publications — IRIC June 13, 2013

RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.

Romeo Y, Moreau J, Zindy PJ, Saba-El-Leil M, Lavoie G, Dandachi F, Baptissart M, Borden K, Meloche S, Roux PP
Oncogene 2013-06-13 ;32( 24 ):2917-26.


Publications — IRIC May 10, 2013

Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.

Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden K
Biochem. Biophys. Res. Commun. 2013-05-10 ;434( 3 ):614-9.


Publications — IRIC May 1, 2013

The Oncogene eIF4E: Using Biochemical Insights to Target Cancer.

Carroll M, Borden K
J. Interferon Cytokine Res. 2013-05-01 ;33( 5 ):227-38.


Publications — IRIC April 15, 2013

eIF4E3, a new actor in mRNA metabolism and tumor suppression.

Volpon L, Osborne MJ, Culjkovic-Kraljacic B, Borden K
Cell Cycle 2013-04-15 ;12( 8 ):1159-60.


Publications — IRIC March 5, 2013

eIF4E3 acts as a tumor suppressor by utilizing an atypical mode of methyl-7-guanosine cap recognition.

Osborne MJ, Volpon L, Kornblatt JA, Culjkovic-Kraljacic B, Baguet A, Borden K
Proc. Natl. Acad. Sci. U.S.A. 2013-03-05 ;110( 10 ):3877-82.


Publications — IRIC January 1, 2013

Mechanisms and insights into drug resistance in cancer.

Zahreddine H, Borden K
Front Pharmacol 2013-01-01 ;4:28.


Publications — IRIC December 11, 2012

MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo.

Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SN, Fang F, Gascoyne RD, Martinez-Climent JA, Glickman JF, Borden K, Wu H, Melnick A
Cancer Cell 2012-12-11 ;22( 6 ):812-24.


Publications — IRIC August 30, 2012

The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation.

Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden K
Cell Rep 2012-08-30 ;2( 2 ):207-15.


Publications — IRIC February 3, 2012

Structural insights into the allosteric effects of 4EBP1 on the eukaryotic translation initiation factor eIF4E.

Siddiqui N, Tempel W, Nedyalkova L, Volpon L, Wernimont AK, Osborne MJ, Park HW, Borden K
J. Mol. Biol. 2012-02-03 ;415( 5 ):781-92.

Load more results
Search filters

Search filters

Open accordion

Search filters

Close accordion
Active filters
Publications
Katherine Borden
Types of content
  • Publications (137)
Principal Investigators
  • Alain Verreault (2)
  • Benjamin Kwok (1)
  • Katherine Borden (137)
  • Philippe P. Roux (1)
  • Pierre Thibault (2)
  • Sylvain Meloche (3)
  • Trang Hoang (1)
Research topics
  • Cell Division & Migration (4)
  • Cell Signaling & Protein Dynamics (5)
  • Chemical & Structural Biology (137)
  • Genomics & Epigenetics (2)
  • Immunology & Hematopoiesis (137)
  • Targeted Therapies & Diagnostics (137)
Years
  • 2022 (5)
  • 2021 (2)
  • 2020 (3)
  • 2019 (8)
  • 2018 (4)
  • 2017 (2)
  • 2016 (3)
  • 2015 (5)
  • 2014 (6)
  • 2013 (9)
  • 2012 (5)
  • 2011 (4)
  • 2010 (4)
  • 2009 (10)
  • 2008 (5)
  • 2007 (3)
  • 2006 (5)
  • 2005 (5)
  • 2004 (4)
  • 2003 (3)
  • 2002 (6)
  • 2001 (4)
  • 2000 (7)
  • 1999 (1)
  • 1998 (6)
  • 1997 (3)
  • 1996 (3)
  • 1995 (2)
  • 1994 (2)
  • 1993 (3)
  • 1992 (2)
  • 1991 (1)
  • 1990 (2)
IRIC - Institute for Research in Immunology and Cancer

Primary navigation

  • About
  • Research
  • Training
  • Valorization
  • Careers
  • Support research
  • Directory
  • Press
  • Tools
  • Contact

IRIC | Université de Montréal
2950, Chemin de Polytechnique
Marcelle-Coutu Pavilion
Montréal, Québec  H3T 1J4
Canada

How to get to IRIC?

Phone
+1 514-343-7770
Fax
+1 514-343-7780

Social networks

Subscribe to the newsletter
Subscribe to the newsletter

Secondary navigation

  • Terms and conditions
  • Privacy policy

© 2003-2023 IRIC. All rights reserved.

Website by Principal